Cell Res: Broad-spectrum resistance of "public antibodies" to the new coronavirus and its mutants

The neutralizing antibodies produced by the human immune system against invading viruses can effectively prevent viral infections

On September 3, 2021, Peking University's School of Life Sciences, Biomedical Frontier Innovation Center (BIOPIC) Su Xiaodong's research group and the partner China Food and Drug Control Institute Wang Youchun's laboratory jointly published the title Structure-based Analyses of Neutralization in Cell Research Antibodies Interacting with Naturally Occurring SARS-CoV-2 RBD Variants research papers systematically and in-depth study of the effects of RBD of various natural mutant strains of SARS-CoV-2 on human-derived neutralizing antibodies, from biochemistry and structural biology The perspective of cell infection and cell infection explains why some antibodies have decreased affinity for mutant strains.

At the beginning of the epidemic, people identified a large number of antibodies that recognize the new coronavirus from the peripheral blood of convalescent patients, especially antibodies that specifically recognize RBD.

In order to study the impact of various mutations of the new coronavirus RBD on the "Public Antibody", this article studied the changes in the binding ability of a variety of public antibodies to a variety of known new coronavirus RBD mutants

Legend: The effect of different mutations in the epitope region of the new coronavirus Spike RBD on the binding and neutralizing activity of the "neutralizing antibody"

　　Further pseudovirus neutralization experiments at the cellular level also clearly showed that the neutralization ability of these "Public Antibody" against most of the new coronavirus mutants has not changed much.

　　The study shows that the "public Antibody" produced in the human body still maintains a good neutralizing effect on different mutant strains of the new coronavirus, which has important practical significance for the fight against the new coronavirus infection and indicates a more optimistic prospect.

　　Finally, in this study, two other high-affinity neutralizing antibodies that are not "Public Antibody" were also studied.

　　Professor Su Xiaodong from Peking University School of Life Sciences, Biomedical Frontier Innovation Center (BIOPIC), and Professor Wang Youchun from China Food and Drug Control Institute are the co-corresponding authors of this article

　　Paper link:

　　https://　　

　　references

　　1.

　　2.

　　3.

　　4.